172 related articles for article (PubMed ID: 18853197)
1. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.
Sharma AP; Filler G
Pediatr Nephrol; 2009 Feb; 24(2):423-4. PubMed ID: 18853197
[No Abstract] [Full Text] [Related]
2. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
Basu B; Mahapatra TK; Mondal N
Pediatrics; 2015 Jul; 136(1):e132-9. PubMed ID: 26101364
[TBL] [Abstract][Full Text] [Related]
3. Rituximab followed by mycophenolate mofetil in children with IgM nephropathy.
Gu J; Xia Y; Mao J; Fu H; Liu A
Indian Pediatr; 2012 Oct; 49(10):831-3. PubMed ID: 23144102
[TBL] [Abstract][Full Text] [Related]
4. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy.
Yang T; Nast CC; Vo A; Jordan SC
Nephrol Dial Transplant; 2008 Jan; 23(1):377-80. PubMed ID: 17981884
[No Abstract] [Full Text] [Related]
5. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
Fujinaga S; Someya T; Watanabe T; Ito A; Ohtomo Y; Shimizu T; Kaneko K
Eur J Pediatr; 2013 Apr; 172(4):513-8. PubMed ID: 23271494
[TBL] [Abstract][Full Text] [Related]
6. Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report.
Bruserud Ø; Håvardstein K
Hematology; 2009 Aug; 14(4):224-6. PubMed ID: 19635186
[TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
[TBL] [Abstract][Full Text] [Related]
8. Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial.
Ravani P; Lugani F; Drovandi S; Caridi G; Angeletti A; Ghiggeri GM
JAMA Pediatr; 2021 Jun; 175(6):631-632. PubMed ID: 33616641
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation.
O'Connell N; Goodyer M; Gleeson M; Storey L; Williams M; Cotter M; O'Marcaigh A; Smith O
Pediatr Transplant; 2014 Feb; 18(1):E22-4. PubMed ID: 24168326
[TBL] [Abstract][Full Text] [Related]
10. [Immunosuppressive therapies for refractory nephrotic syndrome].
Mitarai T
Nihon Jinzo Gakkai Shi; 2010; 52(7):924-7. PubMed ID: 21077342
[No Abstract] [Full Text] [Related]
11. Ofatumumab for rituximab-resistant nephrotic syndrome.
Basu B
N Engl J Med; 2014 Mar; 370(13):1268-70. PubMed ID: 24670185
[No Abstract] [Full Text] [Related]
12. Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia.
Rovelli A; Corti P; Beretta C; Bovo G; Conter V; Mieli-Vergani G
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):596-9. PubMed ID: 18030239
[No Abstract] [Full Text] [Related]
13. Should we consider MMF therapy after rituximab for nephrotic syndrome?
Filler G; Huang SH; Sharma AP
Pediatr Nephrol; 2011 Oct; 26(10):1759-62. PubMed ID: 21533869
[TBL] [Abstract][Full Text] [Related]
14. Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.
Ghiggeri GM; Musante L; Candiano G; Bruschi M; Santucci L; Barbano G; Trivelli A; Rivabella L; Gusmano R; Perfumo F
Pediatr Nephrol; 2007 Nov; 22(11):1953-6. PubMed ID: 17661091
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
Wang J; Mao J; Chen J; Fu H; Shen H; Zhu X; Liu A; Shu Q; Du L
Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and safety of rituximab in pemphigus vulgaris].
Alonso Sánchez A; García Rodríguez S; López Avila A; Rabell Iñigo S
Farm Hosp; 2010; 34(2):98-9. PubMed ID: 20304370
[No Abstract] [Full Text] [Related]
17. [Immunosuppressive therapy update 2010 for ANCA-associated glomerulonephritis and intractable nephrotic syndrome].
Yoshida M
Nihon Jinzo Gakkai Shi; 2010; 52(1):1-9. PubMed ID: 20166533
[No Abstract] [Full Text] [Related]
18. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome.
Kurosu N; Sugiura H; Iwasaki C; Asamiya Y; Kojima C; Moriyama T; Itabashi M; Tsukada M; Takei T; Ogawa T; Yoshida T; Uchida K; Tsuchiya K; Nitta K
Intern Med; 2009; 48(21):1901-4. PubMed ID: 19881243
[TBL] [Abstract][Full Text] [Related]
19. Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution.
Bitzan M; Ouahed JD; Krishnamoorthy P; Bernard C
Pediatr Nephrol; 2008 Aug; 23(8):1355-61. PubMed ID: 18351394
[TBL] [Abstract][Full Text] [Related]
20. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J; Ehrich JH; Querfeld U
Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
